Retrospective Study
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 14, 2015; 21(18): 5524-5531
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5524
Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B
Calvin Q Pan, Sing Chan, Huy Trinh, Alan Yao, Ho Bae, Lillian Lou
Calvin Q Pan, Division of Gastroenterology, Department of Medicine, New York University Langone Medical Center, New York University School of Medicine, New York City, NY 11355, United States
Sing Chan, Sing Chan Endoscopy, Flushing, New York City, NY 11355, United States
Huy Trinh, San Jose Gastroenterology, San Jose, CA 95128, United States
Alan Yao, AE and LY Medical Associates, Flushing, New York City, NY 11355, United States
Ho Bae, Asian Pacific Liver Center, St. Vincent Medical Center, Los Angeles, CA 90057, United States
Lillian Lou, Nexus Development, Palo Alto, CA 94301, United States
Author contributions: All authors have contributed to the paper, are familiar with the contents of the final draft, and agree to be accountable for all aspects of the work; all authors meet the specified criteria for authorship.
Supported by Gilead Sciences; Editorial support was provided by Carol Lovegrove, associated with Elements Communications (Westerham, United Kingdom), and funded by Gilead Sciences.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Calvin Q Pan, MD, Professor, Division of Gastroenterology, Department of Medicine, New York University Langone Medical Center, New York University School of Medicine, 132-21 Forty First Ave, Flushing, New York City, NY 11355, United States. cpan11355@yahoo.com
Telephone: +1-718-8887728
Received: August 7, 2014
Peer-review started: August 8, 2014
First decision: August 27, 2014
Revised: September 16, 2014
Accepted: November 18, 2014
Article in press: November 19, 2014
Published online: May 14, 2015
Processing time: 283 Days and 18.3 Hours
Core Tip

Core tip: Although a substantial proportion of the worldwide hepatitis B virus-infected population is Asian, this is often not reflected in clinical trial populations. Comparison of data from Asian and non-Asian patients is important to provide a better understanding of treatment outcome in Asian populations. Our analysis is the first and largest to compare early (48 wk) response to tenofovir disoproxil fumarate (TDF) in Asian and non-Asian patients during large-scale clinical studies. Overall, TDF demonstrated similar viral suppression, normalization of alanine aminotransaminase and improvements in liver fibrosis, with no resistance, in all cohorts, irrespective of baseline hepatitis B e antigen status and viral load.